Furthermore, dysregulation of matrix metalloproteinase-2 (MMP-2), a key mediator of extracellular matrix remodeling in both DCM and DN, may be modulated by BB therapy, as evidenced by alterations in circulating MMP-2/TIMP-2 levels in CKD patients [61,63]. The gene discussed is MMP2; the disease is familial dilated cardiomyopathy.